Nabiximols — research review 1

…and this is where treatments like nabiximols – that THC:CBD oromucosal spray – become really interesting in the context of aging.

Exactly. We know chronic pain itself isn't just unpleasant; it’s a biological stressor. Research like the GeroScience 2025 study, PMID 39847262, shows painful diabetic neuropathy is linked to accelerated epigenetic aging and telomere shortening compared to painless neuropathy. So, in theory, reducing pain could slow this down.

That makes sense. If uncontrolled pain drives biological aging, then effective pain management should have a positive knock-on effect. But what does the evidence say specifically about nabiximols, or even its drug class, regarding all-cause mortality or a direct impact on biological aging?

This is a crucial distinction. While nabiximols can effectively relieve pain for some, particularly in conditions like MS-related spasticity or cancer pain, the direct evidence linking its use to slowing biological aging or reducing all-cause mortality is currently unestablished. We simply don't have those long-term studies.

So, while the harm of untreated pain on aging is clear, the benefit of nabiximols on aging markers or longevity isn't yet proven, and we must also consider potential long-term risks with any chronic medication.

Precisely. For individuals who genuinely benefit from nabiximols under medical supervision, it can improve quality of life. But we need to be clear: claiming it directly slows aging or reduces all-cause mortality without the evidence is a leap. We must weigh the known benefits for pain relief against the still-unknown long-term impacts on aging and any potential harms like falls or sedation, which can be significant risks for older adults.